申请人:OSI Pharmaceuticals, Inc.
公开号:US07465726B2
公开(公告)日:2008-12-16
Compounds represented by Formula (I):
or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
公式(I)所代表的化合物,或其立体异构体或药学上可接受的盐,是动物,包括人类中至少两种Abl,Aurora-A,Blk,c-Raf,cSRC,Src,PRK2,FGFR3,Flt3,Lck,Mek1,PDK-1,GSK3β,EGFR,p70S6K,BMX,SGK,CaMKII,Tie-2,IGF-1R,Ron,Ret和KDR激酶的抑制剂,用于治疗和/或预防各种疾病和病况,如癌症。